
    
      Subjects will be screened, consented and enrolled at the first visit. Subjects will return to
      the second visit where they are experiencing shortness of breath and will be treated with the
      alphacore. Breathing and vital signs will be measured before, during and after the
      stimulation. The study is concluded on the third visit, 7 days later.
    
  